Non-steroidal and steroidal sulfamates: New drugs for cancer therapy

Molecular and Cellular Endocrinology

Volumn 171, Issue 1-2, 2001, Pages 129-135

  Purohit, A ^a   Woo, L W L ^b   Barrow, D ^c   Hejaz, H A M ^b   Nicholson, R I ^c   Potter, B V L ^b   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

2 methoxyestrone 3 O sulfamate; 667 COUMATE; Breast cancer; Estrone sulfate; Steroid sulfatase

Indexed keywords

2 METHOXYESTRONE 3 O SULFAMATE; ANDROSTENEDIOL; COUMARIN DERIVATIVE; COUMARIN SULFAMATE; ESTRONE; ESTRONE 3 O SULFAMATE; NEW DRUG; OXEPIN SULFAMATE; STEROID; STERYL SULFATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; ESTROGEN ACTIVITY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; STEROID METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COUMARINS; ENZYME INHIBITORS; ESTROGENS; ESTRONE; FEMALE; HUMANS; KINETICS; OXEPINS; RATS; RATS, WISTAR; SULFATASES; SULFONAMIDES; SULFONIC ACIDS; TUMOR CELLS, CULTURED;

EID: 0035931326     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(00)00428-7     Document Type: Article

References (26)

1. Pharmacology of inhibitors of estrogen biosynthesis
2. Steroid sulfatase biosynthesis and processing in normal and mutant fibroblasts
3. New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity
4. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate l7α benzyl (or 4′-tert-butylbenzyl) estra-1,3,5(10)-trienes: combinations of two substituents at position C3 and C17α of estradiol
5. Androstenedione and androst-5-ene-3β, 17β-diol stimulate DMBA-induced mammary tumours - role of aromatase
6. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer
7. Sulphamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral applications
8. Novel oestrogen sulphamates: a new approach to oral hormone therapy
9. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth
10. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
11. Development of potent non-estrogenic estrone sulfatase inhibitors
12. Aromatase inhibitors
13. Aromatase inhibitors - where are we now?
14. The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight
15. Importance of estrogen sulphates in breast cancer
16. Stimulation of cell proliferation and estrogenic response by adrenal C 19-delta-5 -steroids in the ZR-75-1 human breast cancer cell line
17. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells
18. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate
19. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor
20. The development of A-ring modified analogues of oestrone-3-O-sulphamate as steroid sulphatase inhibitors with reduced oestrogenicity
21. The effect of 2-methyoxestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours
22. Sulphatase inhibitors: the rationale for the development of a new endocrine therapy
23. The development of steroid sulphatase inhibitors
24. Use of aromatase inhibitors in breast carcinoma
25. Active site-directed inhibition of estrone sulfatase by non-steroidal coumarin sulfamates
26. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?